Sex differences in HIV-1 viral load and absolute CD4 cell count in long term survivors HIV-1 infected patients from Giurgiu, Romania

Loredana Manolescu1*, Paul Marinescu2

1. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
2. Public Health Direction, Giurgiu, Romania

Abstract

Introduction: Prior studies assessing sex differences correlated with the levels of human immunodeficiency virus (HIV) RNA and absolute CD4 cell count in adults and children, treated or untreated with antiretroviral (ARV) therapy presented conflicting results. Objective: To assess comparative HIV RNA levels and absolute CD4 cell count in men and women from a large cohort of HIV-infected long term survivors patients. Methods: 462 HIV infected patients were analyzed cross-sectionally and longitudinally after being split into three groups: 156 naïve deceased patients, median age at death 10 years, 197 ARV treated patients, median age 17 years and 109 ARV treated patients, median age 23 years followed up until 2011. HIV RNA and absolute CD4 cell count were measured in all patients enrolled in the study. Results: In cross-sectional analysis of 156 naïve patients HIV RNA median levels were lower in females comparing to males, 4.95 vs. 5.73 HIV RNA log10 (copies/ml). Female absolute CD4 cell count was slightly higher, (median 97 vs. 65.5 cells/µL; P = 0.0001). Cross-sectional analysis of 197 ARV treated patients showed a lower log10 HIV RNA level in females compared to males, (P=0.0001), and also lower median CD4 count values in women, 336 cells/µL vs 456 cells/µL in men, P=.0001. Longitudinal analysis revealed statistically significant results: mean log viral loads were lower in females (F=13.90, P= 0.0009) and absolute CD4 cell count was lower in males (F=16.72, P<0.0001), almost across all tested ages. Conclusion: We report steady sex differences in HIV RNA levels and absolute CD4 cell count in ART-treated HIV-infected patients, a fact that may suggest a reevaluation of our current treatment strategies according to sex.

Keywords: HIV, sex differences, absolute CD4 cell count, viral load HIV RNA level.

Rezumat


*Corresponding author: Loredana Manolescu, MD PhD, Carol Davila University of Medicine and Pharmacy, 8 Eroilor Sanitari, Bucharest, Romania.
Tel: 0040723699253; fax:0040214243247; E-mail: manolesculedana@yahoo.com.
Introduction

Several cross-sectional and longitudinal studies assessed sex differences correlated with the levels of human immunodeficiency virus (HIV) RNA and absolute CD4 cell count both in adults and children, treated or untreated with antiretroviral (ART) therapy. In cross-sectional studies women had 0.13–0.35 log10 (2-fold) lower levels of HIV RNA than do men, despite controlling for CD4 cell count (1-6). In longitudinal studies women had 0.33–0.78 log10 (2- to 6-fold) lower levels of HIV RNA than do men (7-10).

Evidence that HIV-infected women have lower HIV RNA levels and higher CD4 cell count comparing to men was attributed to the immunomodulatory effects of sex steroid hormones, such as estrogen and progesterone (11,12). But significant sex differences in HIV RNA levels and CD4 cell count are present in HIV-infected children before the onset of puberty suggesting that intrinsic genetic differences between male and female individuals are unrelated to sex steroid hormone levels and may influence HIV RNA level and CD4 cell count in HIV-infected individuals (13).

In most people infected with HIV, clinical or laboratory evidence of immunodeficiency develops within 10 years of seroconversion, but a few infected people remain healthy for almost a decade. These subjects are termed long-term survivors and they may yield important clues for the study of HIV infection and the development of the acquired immunodeficiency syndrome.

There are 12781 people living with HIV/AIDS in Romania, according to the data provided by Compartiment for Monitoring and Evaluation of HIV/AIDS Data, National Institute of Infectious Diseases Prof. Dr. Matei Bals, at 1st of December 2012. Currently, Romania has a large number of survivors, integrated in the 19-24 age group, who belong to the 1987-1990 cohort (>6000). Almost 10% of them are currently living in the same region, the Giurgiu County (14).

Here we assessed HIV RNA levels and absolute CD4 cell count in a large cohort of HIV-infected patients with an epidemiologic particularity, namely long term survivors, some having experienced multiple therapeutic schemes over time. We undertook a critical epidemiological review of the available evidence concerning whether women have lower levels of human immunodeficiency virus (HIV) RNA than men after several changes in antiretroviral therapy schemes.

Methods

This research was approved by the ethical review board of the Infectious Disease Hospital from Giurgiu County.
Study participants
Data from an initial large cohort of 462 HIV infected individuals from Giurgiu County, Romania was analyzed at different points in time. These patients were born in poor families or abandoned in foster care between 1987 to 1990 and were probably infected in the same way and probably at the same period of time by horizontal route. The majority of patients were HIV diagnosed from 1989 to 1999 but there were 35 patients that were diagnosed later, between 2000 and 2005. The patients were clinically evaluated in day clinic at Giurgiu Infectious Disease Hospital. Many of these patients have begun therapy since 1995 and have experimented between two and five antiretroviral regimens until the end of 2011.

First CD4 and (HIV) RNA evaluations were performed in 1995 for those already diagnosed who started antiretroviral (ARV) therapy at that time. Patients diagnosed after 1995 have been evaluated at the time of HIV diagnosis and if eligible they started ARV therapy. As ARV drugs developed worldwide, they were administered to Romanian patients so their ARV therapy changed along with the improvement of those drugs and according to the need of the patients. From the initial group 33.76% patients died until 2005. About 42.56% of patients were lost from hospital evidence until the end of 2011. For the remaining 23.59% of patients, monitoring of CD4 and HIV RNA was performed until the end of 2011.

Quantitative CD4 and HIV RNA
HIV RNA and absolute CD4 cell count were measured in all the participants enrolled in the study. Absolute CD4 cell count was performed at least twice a year and HIV RNA once a year starting with 1995 until present.

From 1995 until 2005 absolute CD4 cell count was determined from fresh whole blood samples on a 3-color flow cytometer. Plasma HIV RNA levels were measured from fresh blood specimens using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (dynamic range, 20–10 000 000 copies/mL). The tests were conducted in Professor Dr. Victor Babes Infectious Diseases Hospital from Bucharest. Because the dynamic ranges of these assays differed, for combined analyses we assigned all HIV RNA measurements > 500 000 copies/mL as a value of 500 001 copies/mL, and we assigned measurements <400 copies/mL as a value of 399 copies/mL. Log-transformed HIV RNA levels were used for all analyses.

Statistical analyses
Differences in HIV RNA levels and absolute CD4 cell count was evaluated by Fisher's exact test analysis of contingency tables, using GraphPad QuickCalcs (http://www.graphpad.com/quickcalc/index.cfm). Two-tailed P values were reported. P < .05 was considered statistically significant. Median values were compared using the Mann–Whitney Wilcoxon match-pairs signed rank test. Median values were used in all tables due to the fact that they are less affected by the presence of an outlier and are better and more reliable measures of central tendency. Linear regression models were developed with GraphPad Prism 5.0. Linear regression lines showing the relationship of absolute CD4 levels (cells/µL) to age in male and female patients followed longitudinally in group three and linear regression lines showing the relationship of mean HIV RNA levels (log10 copies/mL) to age in male and female patients followed longitudinally in group three were developed.

Analyses of baseline characteristics were performed with either a t test for categorical variables or an F test for continuous variables, to determine whether there were gender differences at baseline. These analyses were performed separately for the three groups, namely, HIV-infected naive children from...
group one, patients treated with ART from group two and ARV treated patients continuously followed over time from group three.

Results

Cohort Characteristics

The total of 462 analyzed HIV infected patients was split into three groups. Group one, 156 deceased patients, median age at death 10 years (limits 7-16) were patients not treated with any ARV regimen. The second group, 197 patients, median age at last investigation 17 years (limits 15-18) was composed by patients followed up only until 2005 due to several reasons such as: change of residence, lack of adherence or enrollment in other AIDS centers. The third group, 109 patients, median age at last investigation 23 years (limits 21-24), were followed up until the end of 2011 (Table 1). All laboratory investigations presented in Table 1 are from their last visit in Giurgiu Day Clinic.

The initial cohort was balanced with regard to sex but differed substantially with regard to the level of immune status and age. In the deceased group the majority, 62.87% were male participants.

Sex differences in HIV RNA levels

In cross-sectional analysis of the 156 deceased patients, HIV RNA median levels were lower in females than in males - 4.95 HIV RNA log_{10}(copies/ml) vs. 5.73 HIV RNA log_{10}(copies/ml). Median HIV RNA values were analyzed with the non-parametric Mann-Whitney Wilcoxon test which showed no statistical significance; (two tailed P value = 0.3458) (Table 2). No association could be found between CD4 count, HIV RNA levels and age at these patients.

When stratifying by CD4 count (Table 4) the female participants maintained lower HIVRNA level for all immunity groups and in the immunosuppressed group the difference was statistically significant, 3.7 Log_{10}(copies/ml) in females vs. 4.5 Log_{10}(copies/ml) in males.

Sex differences in CD4 cell count

In the cross-sectional analysis of the 156 deceased patients, absolute CD4 cell count was a little bit higher in females than males and reached statistical significance, (median 97 vs. 65.5 cells/µL; P = 0.0001), Table 2. Surprisingly, patients with CD4 level >500 cells/µL presented statistically sig-

Table 1. Cohort characteristics

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Total of patients (n = 462)</th>
<th>Deceased ARV naïve (n = 156)</th>
<th>Lost from evidence ARV treated (n = 197)</th>
<th>ARV treated (n = 109)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>231 (50%)</td>
<td>58 (37.17%)</td>
<td>112 (56.85%)</td>
<td>61 (55.96%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>17 (7-24)</td>
<td>10 (7-16)</td>
<td>17 (15-18)</td>
<td>23 (21-24)</td>
</tr>
<tr>
<td>CD4 count (cells/µL)</td>
<td>242 (0-1652)</td>
<td>73 (0-1040)</td>
<td>379 (5-1652)</td>
<td>495.5 (3-1250)</td>
</tr>
<tr>
<td>HIV RNA Level Log_{10}(copies/ml)</td>
<td>3.31 (2.6-5.7)</td>
<td>5.5 (3.5-5.7)</td>
<td>2.9 (2.6-5.7)</td>
<td>2.6 (2.6-5.01)</td>
</tr>
</tbody>
</table>

Values are medians (limits) unless otherwise listed. * P < 0.0001 by Fisher’s and chi-square test. b Log10 (copies/mL): values truncated the narrowest dynamic range of 2.6–5.7.
There was a pronounced sex difference in absolute CD4 cell count among patients with HIV RNA levels $>5 \log_{10}$ (copies/ml), females had statistically significant lower values for absolute CD4 cell count than males (50 cells/µL vs. 418 cells/µL, $P < 0.0001$) (Table 4).

**Longitudinal analysis**

Because CD4 cell count serves as a limited surrogate for disease stage, longitudinal studies allow comparisons between sex groups while controlling for the duration of infection. To further evaluate the effect of sex on age-related changes in HIV RNA level, a linear regression model using longitudinal data from group three was developed. A total of 109 HIV infected patients 23 years, median age at the end of 2011, were retrospectively followed up for their HIV RNA level and absolute CD4 cell count over a period of seventeen years. All this time the patients were heavily ARV treated, the median number of ARV regimens was 3 (limits: 2-5 regimens). HIV RNA level and absolute CD4 cell count were determined by regular basis follow up once a year, median number of evaluation was 9 (range, 3–13).

We found that mean log viral loads were lower for female gender and higher for male gender almost across all ages tested and followed a common slope pattern ($F= 0.265, P=0.6102$) (Figure 1). The differences between sexes were extremely significant ($F=13.90, P= 0.0009$) showing a variation of more than 2 log$_{10}$ for male participants, mean difference 0.9 log$_{10}$ copies/ml, (limits: 0.23-2.1 log$_{10}$ copies/ml). Linear regression analysis of absolute CD4 cell count similarly showed an extremely significant difference between sexes ($F=16.72, P<0.0001$), female patients had higher absolute

---

**Table 2. Age, CD4 Count and HIV RNA level by sex in 156 deceased patients**

<table>
<thead>
<tr>
<th>Deceased patients</th>
<th>Females</th>
<th>Males</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>58</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>Age(years)</td>
<td>10 (7-16)</td>
<td>10 (7-15)</td>
<td>0.3307</td>
</tr>
<tr>
<td>CD4 count (cells/µL)</td>
<td>97 (11-774)</td>
<td>65.5 (50-1040)</td>
<td>0.0001</td>
</tr>
<tr>
<td>HIV RNA Level Log$_{10}$ (copies/ml)</td>
<td>4.95 (4.7-5.1)</td>
<td>5.73 (3.5-5.8)</td>
<td>0.3458</td>
</tr>
</tbody>
</table>

**Table 3. Age, CD4 Count and HIV RNA level by sex in 197 ARV treated patients**

<table>
<thead>
<tr>
<th>Patients lost from evidence</th>
<th>Females</th>
<th>Males</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>112</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Age(years)</td>
<td>17 (15-18)</td>
<td>17(15-18)</td>
<td>0.3307</td>
</tr>
<tr>
<td>CD4 count (cells/µL)</td>
<td>336 (5-1652)</td>
<td>456 (7-1632)</td>
<td>0.0001</td>
</tr>
<tr>
<td>HIV RNA Level Log$_{10}$ (copies/ml)</td>
<td>2.6 (2.6-5.7)</td>
<td>3.6 (2.6-5.7)</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

**Table 4. CD4 cell count by HIV RNA level**

<table>
<thead>
<tr>
<th>HIV RNA Level$^a$ Log$_{10}$ (copies/ml)</th>
<th>n</th>
<th>CD4 count (cells/µL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>female</td>
<td>male</td>
</tr>
<tr>
<td>$&lt;4$</td>
<td>155</td>
<td>461 (5-1652) 384 (7-1632)</td>
</tr>
<tr>
<td>4-5</td>
<td>28</td>
<td>227.5 (86-547) 274 (50-600)</td>
</tr>
<tr>
<td>$&gt;5$</td>
<td>14</td>
<td>50 (7-426) 418 (380-456)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CD4 count$^a$ (cells/µL)</th>
<th>HIV RNA Level Log$_{10}$ (copies/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$&lt;200$</td>
<td>59 3.7 (2.6-5.7) 4.5 (2.6-5.7)</td>
</tr>
<tr>
<td>200-500</td>
<td>67 3.5 (2.6-5.7) 4.1 (2.6-5.4)</td>
</tr>
<tr>
<td>$&gt;500$</td>
<td>71 2.6 (2.6-5.2) 2.8 (2.6-5.7)</td>
</tr>
</tbody>
</table>

$^a$P < .0001 by Fisher’s and chi-square test.

NOTE. Values are medians (limits) unless otherwise listed.
CD4 cell count mean difference 103 cells/µL, (limits: 9-321 CD4 cells/µL) across all tested ages (Figure 2).

Discussion

Even if nowadays in our country and throughout Eastern Europe we have access to high standard tests such as sequencing and genotyping and when starting or changing ARV therapy we take into account resistance mutations or transmitted drug resistance, we must never forget the importance of two simple tests: viral load - HIV RNA levels and absolute CD4 cell count, tests that remain the key laboratory measures used to guide initiation and monitoring of ART. Here we analyzed the differences between these tests according to gender on a unitary cohort of subjects within the same interval of age considered to be long term survivors, revealing that differences in HIV viral load and absolute CD4 cell count between male and female individuals are evident and steady from childhood to adult age.

A recent study (13) found substantial differences in HIV RNA level and CD4 cell percentages between naive HIV-infected boys and girls throughout childhood and before the onset of puberty suggesting that sex hormones are unlikely to be the major driver of the sex disparity in HIV RNA levels.

Prior studies on ARV treated HIV infected individuals clearly established sex differences in HIV RNA levels and CD4 cell parameters among adults but have also presented conflicting results (15,16). There is one study of 158 children receiving ART that found HIV RNA levels to be 0.38 log lower in girls than in boys but found no difference in CD4 cell count or percentage (15). But there are few studies that analyzed differences on HIV RNA level and CD4 cell count in a large number of participants and none over such a long period of time.

For our study we drew data from a large cohort of children, a total of 462 HIV infected pa-
tients analyzed into three groups. 33.76% of the patients were naïve to ARV and 66.23 were ARV experimented. Out of the treated patients 30.62% patients were longitudinally followed up for more than seventeen years. Our cohort is representative because the participants are from the same region, are infected in the same way and were subjected to the same behavioral and epidemiologic risk factors or socioeconomic disparities. The majority of patients came from HIV/AIDS uninfected parents.

Our patients clearly present lower HIV RNA levels in female comparing to male participants in all groups, ARV naïve or treated and by all types of analysis: cross-sectional and longitudinal. Regarding the absolute CD4 cells count, in cross sectional analysis, the levels of CD4 cells were for females slightly elevated in ARV naïve patients group and lower in ARV treated patients group. In longitudinal analysis the difference between sexes was evident and statistical significant: female participants presented higher absolute CD4 cell count levels.

Current World Health Organization (WHO) Pediatric HIV Treatment Guidelines (17) states that viral load is the most sensitive way to detect viral replication. Virological failure is recognized if the child is adherent to their (first-line) ART regimen, more than 24 weeks from initiation of ART, and has a persistent viral load over 5 000 copies/ml. A delay in switching therapy in a child with high levels of viral replication may lead to greater development of resistance and compromise the virological activity of standard second-line regimens. In our longitudinal analysis of viral load girls of 10 and 11 years old presented more than 2 log10 lower HIV RNA levels than boys at the same age.

Because the differences in HIV RNA levels according to sex occurred over a sustained period in time, seventeen years, but were higher in early ages, a change toward the viral threshold for initiation and change of therapy in female children may be considered, with research that shows therapy to be most beneficial when started early. Also under treatment on this segment of population must be taken into account.

In resource-limited settings it may not be feasible to perform viral load testing very often. The absolute CD4 count may be an alternative used to evaluate and choose the moment of therapy change. Differences between genders with regard to this parameter must be considered.

This study has several limitations. HIV RNA levels were truncated at 5.7 log copies/mL, limiting the ability to accurately quantify the effect size of sex at high HIV RNA levels. But the fact that sex differences were stable over time in the longitudinal data analysis makes the influence of such bias less likely. Another potential limitation of this study is that data were combined from 3 groups that differed by age, stage of disease, and HIV RNA assay used; however, each group was balanced with regard to sex, and inclusion in the linear model did not alter the results.

**Conclusions**

We report steady sex differences in plasma HIV RNA levels and absolute CD4 cell count between ART-treated with potent combination therapy, HIV-infected, female and male participants. This result is in partially agreement with previous published studies but was never revealed for this segment of age and for such a long time followed up period. The follow up period covers childhood and teenage. This findings may have implications in understanding sex differences in ARV experimented HIV infected patients and suggest a reevaluation of our current treatment strategies according to sex.

**Declaration of competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

All authors contributed to study design, data interpretation and critical revision of the manuscript.
Acknowledgement

The authors acknowledge the medical staff from Infectious Disease Hospital from Giurgiu County and the staff from Sfanta Maria Foundation for providing the patients’ charts.

References